Eon™ FR Clinical Study Protocol 1064

Not Applicable

Completed

• Conditions: Fat Disorder
• Interventions: Device: eon™ FR 1064 nm device

• Registration Number: NCT03898830
• Lead Sponsor: Dominion Aesthetic Technologies, Inc.

Brief Summary

This study evaluates the treatment of subjects with the eon™ FR 1064 nm device in a single session to thermally induce apoptosis in adipose tissue.

Detailed Description

This study evaluates the treatment of subjects between 18-60 with the eon™ FR 1064 nm device in a single session to thermally induce apoptosis in adipose tissue in the abdomen.

Study Timeline

• Study Start: 2018-12-08
• Primary Completion: 2019-03-22
• Study Completion: 2019-03-22
• Study First Submitted: 2019-03-28
• Study First Submitted QC: 2019-03-29
• Study First Posted: 2019-04-02
• Status Verified: 2020-05
• Last Update Submitted: 2020-05-16
• Last Update Posted: 2020-05-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Body Mass Index (BMI) of 30 kg/m2 or less.
• Healthy male or female between the ages of 21 and 60.
• Had, at least 25 mm thickness adipose tissue on abdomen.
• Able to read, understand and sign the Informed Consent Form (ICF).
• Willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
• Willing to have limited sun exposure for the duration of the study, including the follow-up period.
• Willing to have photographs and ultrasound measurements taken of the treated area, which could be used de-identified in evaluations and could be used de-identified in presentations and/or publications.
• Female subjects were either post-menopausal, surgically sterilized, or used a medically acceptable form of birth control during the entire course of the study.
• Female subjects with child bearing potential were willing to take a urine pregnancy test and the result must be negative.
• Agreed to maintain their current diet and exercise habits and not be specifically trying to lose weight.

Exclusion Criteria

• Aesthetic fat reduction procedure in the treatment area within the previous year.
• Age less than 21 or greater than 60 years old.
• Female subject pregnant or planning to become pregnant during the study duration,
• Had an infection, dermatitis or a rash in the treatment area.
• Had tattoos or jewelry in the treatment area.
• Had a history of keloid scarring, hypertrophic scarring or of abnormal wound healing.
• Had a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
• Had a history of a known bleeding disorder.
• Had a known photosensitivity to the study laser wavelength, history of ingesting. medications known to induce photosensitivity, or history of seizure disorders due to light.
• Had known collagen, vascular disease or scleroderma.
• Underwent a surgery or procedure in the treatment area within 6 months of treatment, which is still healing.
• Had underwent a fat reduction procedure in the treatment area within the past 12 months.
• Had a significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy.
• Underwent systemic chemotherapy for the treatment of cancer.
• Used gold therapy for disorders such as rheumatologic disease or lupus.
• Participated in a study of another device or drug within three months prior to enrollment or during the study.
• As per the investigator's discretion, the subject had any physical or mental condition which might make it unsafe for the subject to participate in this study.
• Concurrent use of steroids or secondary rheumatoid drugs.
• Prior liposuction or a tummy tuck in the study area.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
eon™ FR 1064 nm device	eon™ FR 1064 nm device	Patient will be treated with the eon™ FR 1064 nm device

Primary Outcome Measures

Name	Time	Method
Photographic Evaluations as a Measure of Effectiveness	12 weeks	Photographs of the treatment area will be obtained at baseline and 12 weeks post treatment and be evaluated by blinded independent readers to correctly identify pre-treatment (baseline) photographs compared to 12 weeks post treatment photographs in order to determine effectiveness of device.

Secondary Outcome Measures

Name	Time	Method
Ultrasound Measurement to Evaluate Reduction in Adipose Layer Thickness	12 weeks	Ultrasound of the treatment area will be performed and evaluated in comparison to the baseline results to determine the reduction in adipose layer thickness.
Circumferential Measurements to Evaluate Reduction in Adipose Layer Thickness	12 weeks	Circumferential measurements of the treatment area will be completed and evaluated in comparison to the baseline results to determine the reduction in adipose layer thickness.
Subject Questionnaire to determine Subject Satisfaction	12 weeks	Subject Questionnaires will be completed by subjects at the end of study to determine the subject satisfaction with procedure.

Trial Locations

Locations (3)

Laser & Skin Surgery Center of Northern; 🇺🇸 Sacramento, California, United States

Miami Dermatology & Laser Research; 🇺🇸 Miami, Florida, United States

Fiala Aesthetics; 🇺🇸 Altamonte Springs, Florida, United States